Literature DB >> 23541547

Risk factors for readmission after lower extremity procedures for peripheral artery disease.

Todd R Vogel1, Robin L Kruse.   

Abstract

OBJECTIVE: As pressure to contain health care costs increases, there has been greater scrutiny of readmissions in the vascular surgery population. The objective of this study was to evaluate postoperative readmissions after open and endovascular lower extremity (LE) procedures for peripheral artery disease (PAD).
METHODS: A retrospective cohort study was performed of elective adult inpatients with PAD and LE procedures which were selected from the Health Facts database (Cerner Corporation, Kansas City, Mo) between October 2008 and December 2010 using International Classification of Disease, 9th Clinical Modification diagnosis codes (claudication, rest pain, and ulceration/gangrene) and procedure codes for LE revascularization (endovascular and open). Multivariable logistic regression and χ(2) were used to compare patients who received endovascular and open procedures. The Charlson Comorbidity Index, comorbid diagnoses, and laboratory results were used to adjust for confounding. The main outcome measure evaluated was readmission ≤ 30 days of discharge.
RESULTS: Of 463,362 index admissions, 16,574 patients were identified with a diagnosis of PAD. Combining PAD with elective LE procedures during the index admission, 777 underwent open and 681 underwent endovascular procedures. Unadjusted readmission rates for open and endovascular procedures for claudication, rest pain, and ulceration/gangrene were 10.2% vs 11.3% (P = .69), 14.0% vs 18.2% (P = .43), and 21.1% vs 19.5% (P = .69), respectively. Readmission increased by the severity of the diagnosis for open and endovascular procedures (P = .0006). Men comprised 58% of the cohort; readmission rates were not statistically different by sex (P = .19). Race was not associated with procedure performed (P = .16), but nonwhite race was associated with more severe PAD (P < .0001). After adjusting for race, sex, comorbidities, length of stay, and laboratory values outside of normal reference ranges, the association between an endovascular procedure and readmission was not statistically significant (odds ratio, 1.28; 95% confidence interval, 0.94-1.75).
CONCLUSIONS: Less invasive endovascular procedures were not associated with decreased readmission rates compared with open surgery. The overall readmission rate for claudicant patients was 10.7%, which was unexpectedly high. Predictors of readmission included male sex, longer hospital stays, hospital infection, elevated aspartate aminotransferase, and high numbers of medications ordered and dispensed. Further examination exploring reasons for readmission are required to decrease readmission rates in the vascular surgery population.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541547     DOI: 10.1016/j.jvs.2012.12.031

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  13 in total

1.  Using same-hospital readmission rates to estimate all-hospital readmission rates.

Authors:  Andrew A Gonzalez; Terry Shih; Justin B Dimick; Amir A Ghaferi
Journal:  J Am Coll Surg       Date:  2014-05-27       Impact factor: 6.113

2.  Risk factors and indications for readmission after lower extremity amputation in the American College of Surgeons National Surgical Quality Improvement Program.

Authors:  Thomas Curran; Jennifer Q Zhang; Ruby C Lo; Margriet Fokkema; John C McCallum; Dominique B Buck; Jeremy Darling; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2014-06-28       Impact factor: 4.268

Review 3.  General and vascular surgery readmissions: a systematic review.

Authors:  Jason T Wiseman; Amanda M Guzman; Sara Fernandes-Taylor; Travis L Engelbert; R Scott Saunders; K Craig Kent
Journal:  J Am Coll Surg       Date:  2014-05-22       Impact factor: 6.113

4.  Thirty-day hospital readmission and emergency department visits after vascular surgery: a Canadian prospective cohort study.

Authors:  Muzammil H Syed; Mohamad A Hussain; Zeyad Khoshhal; Konrad Salata; Beidaa Altuwaijri; Bertha Hughes; Norah Alsaif; Charles de Mestral; Subodh Verma; Mohammed Al-Omran
Journal:  Can J Surg       Date:  2018-08       Impact factor: 2.089

5.  Rates and predictors of readmission after minor lower extremity amputations.

Authors:  Robert J Beaulieu; Joshua C Grimm; Heather Lyu; Christopher J Abularrage; Bruce A Perler
Journal:  J Vasc Surg       Date:  2015-03-28       Impact factor: 4.268

6.  Hospital readmissions after elective lower extremity vascular procedures.

Authors:  Todd R Vogel; Jamie B Smith; Robin L Kruse
Journal:  Vascular       Date:  2017-09-20       Impact factor: 1.285

7.  Risk factors for 30-day unplanned readmission following infrainguinal endovascular interventions.

Authors:  Thomas C F Bodewes; Peter A Soden; Klaas H J Ultee; Sara L Zettervall; Alexander B Pothof; Sarah E Deery; Frans L Moll; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-02       Impact factor: 4.268

8.  Endovascular Versus Open Revascularization for Peripheral Arterial Disease.

Authors:  Jason T Wiseman; Sara Fernandes-Taylor; Sandeep Saha; Jeffrey Havlena; Paul J Rathouz; Maureen A Smith; K Craig Kent
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

9.  Risk Factors for 30-Day Hospital Re-Admission with an Infectious Complication after Lower-Extremity Vascular Procedures.

Authors:  Joseph C Melvin; Jamie B Smith; Robin L Kruse; Todd R Vogel
Journal:  Surg Infect (Larchmt)       Date:  2017-02-08       Impact factor: 2.150

10.  Thirty-day hospital readmission and emergency department visits after vascular surgery: a Canadian prospective cohort study.

Authors:  Muzammil H Syed; Mohamad A Hussain; Zeyad Khoshhal; Konrad Salata; Beidaa Altuwaijri; Bertha Hughes; Norah Alsaif; Charles de Mestral; Subodh Verma; Mohammed Al-Omran
Journal:  Can J Surg       Date:  2018-06-01       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.